PAROXETINE HYDROCHLORIDE Drug Patent Profile

« Back to Dashboard

When do Paroxetine Hydrochloride patents expire, and what generic alternatives are available?

Paroxetine Hydrochloride is a drug marketed by Annora Pharma, Apotex Inc, Novitium Pharma, Alembic, Aurobindo Pharma Usa, Cadila Pharms Ltd, Cspc Ouyi, Epic Pharma Llc, Lannett Co Inc, Lupin, Prinston Inc, Sciecure Pharma Inc, Apotex, Aurobindo Pharma, Chartwell Rx, Jubilant Generics, Mylan, Oxford Pharms, Pharmobedient, Roxane, Sun Pharm Inds Inc, Teva Pharms, Upsher Smith Labs, and Zydus Pharms Usa. and is included in twenty-six NDAs.

The generic ingredient in PAROXETINE HYDROCHLORIDE is paroxetine hydrochloride. Forty-five suppliers are listed for this compound. Additional details are available on the paroxetine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Paroxetine Hydrochloride

A generic version of PAROXETINE HYDROCHLORIDE was approved as paroxetine hydrochloride by APOTEX on July 30^th, 2003.

Summary for PAROXETINE HYDROCHLORIDE

US Patents:	0
Applicants:	24
NDAs:	26
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PAROXETINE HYDROCHLORIDE

Paragraph IV (Patent) Challenges for PAROXETINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PAXIL CR	Extended-release Tablets	paroxetine hydrochloride	37.5 mg	020936	1	2009-05-19
PAXIL CR	Extended-release Tablets	paroxetine hydrochloride	25 mg	020936	1	2005-09-09

US Patents and Regulatory Information for PAROXETINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms	PAROXETINE HYDROCHLORIDE	paroxetine hydrochloride	TABLET;ORAL	077082-003	Jun 29, 2007		DISCN	No	No
Chartwell Rx	PAROXETINE HYDROCHLORIDE	paroxetine hydrochloride	TABLET;ORAL	076618-004	Aug 15, 2005	AB	RX	No	No
Apotex	PAROXETINE HYDROCHLORIDE	paroxetine hydrochloride	TABLET;ORAL	075356-003	Jul 30, 2003	AB	RX	No	No

Paroxetine Hydrochloride Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

What are the key characteristics of the paroxetine hydrochloride market?

Paroxetine hydrochloride is a selective serotonin reuptake inhibitor (SSRI) primarily prescribed for depression, anxiety disorders, and obsessive-compulsive disorder (OCD). It has a well-established patent and manufacturing process, with global sales exceeding USD 1.3 billion annually. Key growth drivers include increasing mental health awareness, expanding indications, and rising prescription rates in emerging markets.

What are the market fundamentals and competitive landscape?

Market Size and Growth

• 2022 global sales: USD 1.35 billion
• Compound annual growth rate (CAGR): 3-5% over the next five years
• Major markets: North America (50%), Europe (20%), Asia-Pacific (20%), rest of the world (10%)

Key Producers and Patent Status

• Original patent expired in 2003, leading to generic entry.
• Top branded formulations include Paxil (GSK), followed by generics dominating the market.
• No current patent protections, emphasizing price competition.

Pricing and Revenue Dynamics

• Generic prices are 30-50% lower than branded formulations.
• Revenue is driven by volume rather than price premium, with generics accounting for 80% of global sales.

Regulatory Environment

• Regulatory approval for generic formulations is streamlined due to established safety profiles.
• Ongoing monitoring for adverse effects influences prescriber confidence and market growth.

What are the key R&D and manufacturing considerations?

Development and Formulation

• No significant proprietary innovation is expected, as the compound's patent has expired.
• Focus shifts toward formulation improvements, bioavailability, and delivery systems.

Manufacturing Landscape

• Large-scale production involves standard synthetic routes with high yield (above 85%).
• Manufacturing costs are competitive, with raw materials like 4-chlorobenzotrifluoride and piperidine derivatives readily available.

What are potential investment risks and barriers?

• Patent expiration historically led to price erosion and revenue decline for original developers.
• Competitive pressure from generics limits pricing power and profit margins.
• Regulatory changes or safety concerns could impact volumes.

How might future trends influence the investment outlook?

Market Expansion

• Increasing prescription rates in Asia-Pacific due to rising mental health awareness and healthcare infrastructure improvements.
• Potential new indications or combination therapies could open additional revenue streams.

Generic Competition and Price Erosion

• Continued erosion of margins as more generics enter markets.
• Consolidation of manufacturers could lead to pricing stabilization or increased bargaining power.

Regulatory and Social Factors

• Updated clinical guidelines may influence prescribing behavior, favoring or disfavoring paroxetine use.
• Growing focus on mental health treatment accessibility supports demand growth.

Financial metrics and valuation considerations

Metric	Current Figures	Trends
Market size (2022)	USD 1.35 billion	Stable with moderate growth
Gross margin (generics)	40-60%	Declining due to price competition
R&D investment	Minimal	Focus on formulation innovation
Production costs	Low	Mature manufacturing processes

Valuation approaches should account for declining branded revenues, the competitive landscape, and the emergent growth in underserved markets. An analysis of company-specific product portfolios, pipeline developments, and market entry strategies is vital.

Key takeaways

• The paroxetine hydrochloride market is mature, with major revenue driven by generics.
• Patent expirations have resulted in price declines and increased competition.
• Future growth hinges on expanding regional access, new formulations, and potential indications.
• Margins are under pressure; profits depend on manufacturing efficiency and market penetration.
• Regulatory and social factors could significantly influence demand trajectory.

FAQs

1. What is the primary therapeutic use of paroxetine hydrochloride?
It treats depression, anxiety, OCD, and related mental health conditions.

2. Has patent protection expired for paroxetine hydrochloride?
Yes, patent protection expired in 2003, leading to widespread generic availability.

3. What are the main risks for investors in this market?
Price erosion from generic competition, regulatory changes, and potential safety concerns.

4. Are there new formulations or indications for paroxetine?
Research focuses on formulation enhancements; no major new indications are currently approved.

5. How does regional growth potential affect investment decisions?
Emerging markets, especially in Asia-Pacific, present expansion opportunities due to increasing healthcare access.

---

References

[1] Euromonitor International. (2022). Mental health pharmaceuticals report.

[2] FDA. (2022). Paroxetine hydrochloride official approval documents.

[3] IMS Health. (2022). Global pharmaceutical market data.

[4] MarketWatch. (2023). Paroxetine market analysis and forecasts.